Boston Scientific Beats on Top and Bottom Line (BSX)

Boston Scientific Corporation

reports Q2 EPS $0.06 vs consensus of $0.03. Boston Scientific reports Q2 revenue $1.93 billion vs consensus of $1.91 billion. BSX said that its market share in the global drug-eluting stent (

) market was 38%; it also noted increased Endoscopy sales of 8 percent. "I am proud of the way the organization executed in a number of key areas during the quarter," said Ray Elliott, President and Chief Executive Officer of Boston Scientific. He added, “In CRM, we finished the quarter well ahead of where we expected to be, thanks to exceptional execution by the sales team and everyone else involved in our recovery. The continued success of our PROMUS Element rollout in Europe was another example of outstanding execution to go along with a very strong 46 percent U.S. DES market share. Once again, our Endoscopy and Women's Health businesses turned in excellent results. In all, 44 percent of our sales in the quarter came from new products, a testament to the building strength of our R&D pipeline." Shares of BSX are higher in the after-hours by 3.67%. Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties, including cardiac rhythm management, electrophysiology, interventional cardiology, peripheral interventions, neurovascular, endoscopy, urology, women's health and neuromodulation.